Background Neutrophil-mediated inflammation was recently identified as an active contributor to athero-progression. Therapeutic strategies inhibiting neutrophil degranulation or recruitment were hypothesized to positively impact on plaque vulnerability. In this study, we investigated whether treatment with the recently discovered agonist of the Mas-related G-coupled receptor type D (MrgD) alamandine would impact on neutrophil degranulation in vivo and in vitro.
Introduction
Emerging evidence suggests that neutrophil activation plays a pathophysiological role in atherogenesis and its acute complications [1, 2] . Animal models of both early and advanced phases of the disease demonstrated that neutrophils infiltrate atherosclerotic plaques [3, 4] . Subsequently, neutrophil degranulation (both intraplaque and in the systemic circulation) was associated with atherosclerotic plaque vulnerability [5] . In human beings, higher intraplaque neutrophil content was shown in symptomatic as compared with asymptomatic carotid plaques [6] . Accordingly, high plasmatic and arterial levels of the neutrophil granule product myeloperoxidase were found in human and mouse cerebral aneurisms, a condition favouring haemorrhagic stroke [7] . Other neutrophil proteinases, such as matrix metalloproteinase (MMP)-8 and MMP-9, were also positively associated with the atherosclerotic risk [8, 9] , suggesting that these cells are an important source of degrading a These authors contributed equally as last author to this work.
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enzymes that actively cause damage in chronic vascular diseases including aneurysm. The renin-angiotensin system (RAS) was recently identified as a regulator of neutrophil-mediated processes in aneurysm formation and atherosclerotic plaques. In particular, in both humans and mice, neutrophils were shown to infiltrate the aortic intima and release MMP-9 in response to angiotensin (Ang) II stimulation [10] . On the other hand, treatment with the vasoactive peptide Ang-(1-7), an agonist of the Mas receptor, led to reduced atherosclerotic vulnerability and decreased neutrophil and MMP-9 intraplaque content [11] . These studies clearly support RAS as a potent regulator of deleterious pro-atherosclerotic activities of neutrophils [12] . During studies of newly discovered and more selective agonists of the Mas-related G-coupled receptor type D (MrgD), the peptide alamandine was recently identified as being generated by catalysis of Ang A via ACE2 or directly by aspartate decarboxylation from Ang-(1-7) [13] . In this study, we hypothesized that this endogenous peptide might actively interfere with neutrophil-mediated pathophysiological processes in atherogenesis. Therefore, we tested whether treatment with alamandine affects neutrophils as well as other inflammatory mediators in a mouse model of carotid atherogenesis (ApoE À/À mice implanted with a carotid 'cast' device). This model of shear stress-induced atherogenesis was previously shown to determine different carotid plaque phenotypes within carotids that could somehow mimic high heterogeneity of human lesions [14] . During further tests, we verified the role of alamandine in the in vitro degranulation of neutrophils isolated from ApoE À/À mice.
Materials and methods

Mouse model of atherogenesis and treatment
Apolipoprotein E-deficient mice (ApoE À/À ) in a C57BL/6J background were purchased from Jackson Laboratories (Les Oncins, France). The 15-week-old animals were transferred to receive a Western-type diet consisting of 15% (wt/wt) cocoa butter and 0Á25% (wt/wt) cholesterol (Diet W; AbDiets, Lage, Germany) for an additional 11 weeks. After the first 2 weeks of Western diet, the shear stress in the right common carotid artery was altered by the surgical placement of a 'cast' device, as previously described [3, 15, 16] . The device induced low shear stress (LSS) in the carotid region upstream of the blood flow and oscillatory shear stress region (OSS) in the region downstream from the cast. The LSS and OSS carotid portions were characterized by the formation of atherosclerotic plaques that were collected at mouse euthanasia (9 weeks after surgery). At week 6 after cast implantation, ApoE À/À mice were anaesthetized using inhaled isoflurane and an incision in the midscapular region was made, through which a mini osmotic pump (Alzet model 2004; Johnson & Johnson, New Brunswick, NJ, USA) was inserted for subcutaneous drug administration. This took place during the last 4 weeks before euthanasia (from week 6 to week 9 of cast implantation). Mice were randomly assigned to subcutaneously receive vehicle (NaCl 0Á15 M) or alamandine (24 lg/kg/h; purchased from Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA; cat. # 002-10). Animals were sacrificed under anaesthesia (ketamine and xylazine, 100 and 15 mg/kg, respectively) followed by blood sampling via cardiac puncture and cardiac perfusion of phosphate-buffered saline. This animal study was approved by the local ethics committee and Swiss authorities and conformed to the 'position of the American Heart Association on Research Animal Use'.
Atherosclerotic plaque processing and immunohistochemistry
Mouse carotid artery was macroscopically cut into three portions: the region upstream of the cast device (LSS), the region of the cast device [characterized by high shear stress (HSS)] and the region downstream of the cast (OSS). The obtained portions were immediately frozen in OCT. As previously described [14, 15] , no plaques were detected in HSS regions (data not shown). Mouse aortic sinuses as well as LSS and OSS carotid plaques were serially cut into 5-lm transversal sections. Five sections from mouse aortic roots and eleven sections from LSS and OSS carotid plaques were fixed in acetone and immunostained with specific antibodies: anti-mouse CD68 (macrophages; ABD Serotec, Dusseldorf, Germany), anti-mouse Ly-6G (neutrophils; BD Pharmingen TM , San Jose, CA, USA) and antimouse MMP-9 (R&D Systems Inc, Minneapolis, MN, USA). Quantifications were performed using the METAMORPH software (Nashville, TN, USA). Results for other parameters were calculated as percentages of stained area over total lesion area or a number of infiltrating cells per mm 2 of lesion area [3, 14, 16] .
Oil Red O staining for lipid content
Five sections of mouse aortic sinus and eleven sections of LSS and OSS carotid plaques were stained with Oil Red O, as previously described [14] . Sections of plaques were counterstained with Mayer's hemalun and rinsed in distilled water. Quantifications were performed using the METAMORPH software. Data were calculated as percentages of stained area on total lesion area.
Sirius red staining for collagen content
Five sections of mouse aortic sinus and eleven sections of LSS and OSS carotid plaques were rinsed with water and incubated with 0Á1% Sirius red (Sigma Chemical Co, St Louis, MO, USA) in saturated picric acid for 90 min. Sections were rinsed twice with 0Á01 N HCl for 1 min and then immersed in water. After dehydration with ethanol for 30 s and cover slipping, the sections were photographed with identical exposure settings under ordinary polychromatic or polarized light microscopy. Total collagen content was evaluated under polychromatic light. Interstitial collagen subtypes were evaluated using polarized light illumination; under this condition, thicker type I collagen fibres appeared orange or red, whereas thinner type III collagen fibres were yellow or green [14] . Quantifications were performed with METAMORPH software. Data were calculated as percentages of stained area over total lesion area.
Measurements of serum inflammatory molecule levels
Colorimetric enzyme-linked immunosorbent assay (ELISA) kits to measure serum CXCL1, CCL2, pro-matrix metalloproteinase (MMP)-9, myeloperoxidase (MPO) and tissue inhibitor of metalloproteinase-1 (TIMP-1) levels (all from R&D Systems), and serum MMP-8 levels (Uscn Life Science Inc., Hubei, China) were used following manufacturer's instructions. The limit of detection was 15Á6 pg/mL for CXCL1, 3Á9 pg/mL for CCL2, 31Á25 pg/mL for pro-MMP-9, 250 pg/ mL for MPO, 37Á5 pg/mL for TIMP-1 and 312Á5 pg/mL for MMP-8. Mean intra-and interassay coefficients of variation (CV) were below 6%.
PCR
Total RNA was extracted from mouse neutrophils and atherosclerotic aorta with Trizol reagent (Ambion, Carlsbad, CA, USA), following the manufacturer's instructions. The concentration and purity of RNA were determined by spectrophotometry analysis, and cDNA was prepared from 1000 ng total RNA using the ImProm-II Reverse Transcription kit Mouse characteristics Vehicle-treated mice (n = 8) Alamandine-treated mice (n = 9) P-value Serum metabolism and lipids
Free fatty acids, mM
Data are expressed as median (interquartile range). P-value calculated according to Mann-Whitney U-test. 
Mouse neutrophil degranulation assay
Neutrophils were obtained from 11-week-old ApoE À/À mice under a normal chow diet after an intraperitoneal injection of 4% thioglycollate solution, as previously described [17] . The peritoneal lavage fluids of mice (n = 14) were used. Neutrophils were resuspended in culture medium (serum-free RPMI 1640 medium containing 25 mM Hepes) and cultured at 5 9 10 5 cells per well. The cells were pre-incubated for 60 min in the presence or absence of control medium or different doses (1 9 10 À7 to 1 9 10 À4 M) of alamandine. Then, a control medium or 10 ng/mL phorbol-12-myristate-13-acetate (PMA, positive control from Sigma-Aldrich, Buchs, Switzerland) was added for an additional 30 min at 37°C in a humidified atmosphere of 5% CO 2 in polystyrene plates without washing. The cell supernatants were collected to be tested for degranulation of pro-MMP-9 and MPO. Levels of pro-MMP-9 and MPO in mouse neutrophil supernatants were assessed by the same ELISA kits from R&D systems that were used to detect these molecules in mouse serum.
Statistical analysis
Statistical analyses were performed with IBM SPSS STATISTICS for Windows, Version 23.0 (IBM Corp., Armonk, NY, USA). Continuous variables are presented as median [interquartile range (IQR)]. Two group comparisons were then performed using a two-tailed t-test (paired and unpaired) or nonparametric Mann-Whitney U-test when the normality assumption of variable distribution was violated. Finally, one-way ANOVA was used for multiple group comparison. A two-sided Pvalue < 0Á05 was considered statistically significant.
Table 3 T helper cell polarization in lymphatic tissues
Marker (mRNA fold increase)
Vehicle-treated mice (n = 8)
Alamandine-treated mice (n = 9) P-value Lymph nodes
Data are expressed as median (IQR). P-value calculated according to Mann-Whitney U-test.
Results
Treatment with alamandine does not affect the lipid profile and intraplaque lipids in aortic root and carotid plaques
The potential effects of alamandine treatment on metabolic parameters were assessed at mouse euthanasia. Treatment with alamandine did not induce any significant change in the serum lipid profile, glucose or inflammatory chemokines (i.e. CCL2 and CXCL1) as compared with the control vehicle (Table 2) . Accordingly, treatment with alamandine did not affect intraplaque lipid content in aortic root plaques or in carotid LSS and OSS atheroma as compared with the control vehicle (Fig. 1a,b) .
Treatment with alamandine does not affect intraplaque macrophage or neutrophil content within atherosclerotic plaques
The potential effects of treatment with alamandine on inflammatory mechanisms regulating atherogenesis were investigated within lymphoid organs (i.e. lymph nodes and spleen) and atherosclerotic plaques. No difference on T-cell subsets (Th1/ Th2/TregTh17) was observed within lymphoid organs between alamandine-and vehicle-treated mice (Table 3) . Accordingly, treatment with alamandine was not associated with any change in total macrophage content within both aortic root and carotid LSS and OSS plaques (Fig. 2a,b) . In addition, treatment with alamandine did not affect neutrophil intraplaque content as compared with the control vehicle (Fig. 2c,d ). Finally, treatment with alamandine was not associated with any modification of collagen content as compared with the control vehicle within both aortic root and carotid LSS and OSS plaques (Fig. 3a,b) .
Treatment with alamandine is associated with a reduction in circulating and intraplaque levels of MMP-9
We first investigated whether MrgD (the alamandine receptor) was expressed in neutrophils isolated from ApoE À/À mice.
The mRNA expression of Mrgprd was present in neutrophils isolated from ApoE À/À mouse donors in a comparable manner to the positive-control tissue (the aorta from an ApoE À/À mouse; Fig. 4a ). The mRNA quality was confirmed by the expression of the housekeeping gene Hprt (Fig. 4b) . Treatment with alamandine was associated in vivo with a reduction in circulating levels of some neutrophil granule products (i.e.
MMP-9 and MPO) as compared with vehicle-treated mice (Table 4) . Also, a nonsignificant (P = 0Á093) reduction in MMP-8 serum levels was observed in alamandine-treated mice as compared with vehicle (Table 4) . Reduction in these proteases and myeloperoxidase was not accompanied by any modification in TIMP-1 serum levels between the study groups (Table 4) . Within mouse plaques, treatment with alamandine significantly reduced MMP-9 content in aortic roots, but not in carotid LSS and OSS portions (Fig. 5a,b) . Accordingly, a significant reduction in MMP-9 mRNA expression was reported in aortas from atherosclerotic mice treated with alamandine as compared with vehicle-treated mice (Table 5) . Importantly, no difference in mRNA levels of other MMPs, Mpo, Timp-1 as well as pro-atherosclerotic molecules (i.e. Cxcl1, Cxl2, Tnf) was noted between alamandine-and vehicletreated mice (Table 5) . Pretreatment with different concentrations of alamandine was finally tested on PMA-induced degranulation of neutrophils isolated from ApoE À/À mice. Pre-incubation with 10 À4 M alamandine abrogated neutrophil degranulation of both MMP-9 and MPO in response to PMA (Fig. 6a,b) . The alamandine-mediated effect on degranulation was dosedependent (Fig. 6a,b) . Both in vivo and in vitro experiments suggest that treatment with alamandine was associated with a beneficial reduction in the amount of proteases and MPO of potential neutrophil origin.
Discussion
The main finding of this study is that treatment with alamandine can reduce neutrophil degranulation in vitro. In vivo, treatment with comparable concentrations of alamandine was associated with abrogation of the same neutrophil granule enzymes in the systemic circulation and within aortic root plaques, but not in carotid arteries. The apparent discrepancy between plaques at different sites of atherosclerosis might reflect high heterogeneity of the lesions that was also described in human beings [14] . Among other ligands [such as Ang-(1-7)], alamandine was previously shown to activate MrgD-mediated anti-inflammatory pathways [13] . This receptor was shown to protect mice from both acute injury and chronic inflammatory injury. For instance, the genetic deletion of Mas receptor in C57BL/6 mice resulted in an increased inflammatory response to LPS injection, suggesting a potent anti-inflammatory role of this receptor in acute systemic inflammatory disorders [18] . In a neonatal rat model of chronic lung disease (CLD), treatment with agonists of the Mas receptor was associated with lower pulmonary influx of neutrophils, thus potentially reducing lung injury [19] . Confirming these results, a recent study using male Sprague-Dawley rats, Balb/c and C57Bl6/J mice with acute lung injury showed that antagonism of the Mas receptor with A779 was able to restore neutrophil infiltration within the lungs [20] . The modulation of neutrophil degranulation was also suggested as a promising therapeutic target against atherogenesis. Evidence from our research group supported an active role for neutrophil pro-inflammatory functions (i.e. degranulation) in plaque vulnerability [5, 9] . Our in vivo experiments demonstrated that treatment with alamandine was associated with abrogation of neutrophil granule enzymes in both the systemic circulation and aortic root plaques. In particular, marked reductions in MMP-9 and MPO levels were observed in alamandine-treated mice as compared with the control vehicle. Importantly, we also observed a significant reduction in MMP-9 mRNA expression levels within atherosclerotic aortic tissues. These results might suggest that alamandine treatment could be associated with a reduced expression (and not only a release) of proteases in atherogenesis. Although MMP-9, MMP-8 and MPO might be released by other cell subsets (i.e. macrophages) [21] [22] [23] , neutrophils still represent a major source of these toxic compounds within mouse plaques [14] , where their activity might degrade the protective collagen in the fibrous cap and increase the risk of plaque rupture. Although alamandine treatment was able to reduce neutrophil proteases, this benefit was not accompanied by any amelioration in the plaque structural stability. Intraplaque collagen content was similar in alamandine-and vehicle-treated mice. This apparent discrepancy might be explained by the fact that neutrophil-mediated injury is not the only one determinant of plaque vulnerability. By interfering with the RAS, alamandine might in principle affect mouse blood pressure or trigger adverse pro-atherosclerotic activities that counterbalance the benefits of neutrophil inhibition. Unfortunately, we were not able to assess all mouse hemodynamic and inflammatory parameters in this pilot study. However, this point must certainly be acknowledged as the main study limitation and deserves additional investigation with targeted monitoring equipment. To add information on other potential 'pleiotropic effects' of alamandine, we tested to verify whether this peptide was able to interfere with intraplaque macrophages and Th lymphocyte polarization in lymphoid organs. As no difference between groups was shown, we could speculate that alamandine treatment might selectively affect neutrophils without inducing a potential systemic immunosuppression. One of the main limitations of this study is represented by the fact that we were able to treat animals with a single dose of alamandine, instead of testing a doseresponse curve as compared with placebo. Therefore, the lack of efficacy of alamandine treatment on coronary plaque composition deserves further investigations. In addition, a longitudinal study of the effects of alamandine on plaque composition also still needs to be studied. Therefore, this study has to be considered as 'pilot' investigation. Another study limitation is represented by the fact that the presence of the Mas-related G-coupled receptor type D on mouse neutrophils was demonstrated by PCR. Additional technical methods, such as binding assays [13] , might be appropriate to further confirm this discovery. In summary, we showed that pretreatment with alamandine was able to reduce neutrophil degranulation in vitro. In vivo, alamandine treatment did not affect macrophage-or Th-cellmediated inflammation, but impacted on systemic and intraplaque proteases of potential neutrophil origin. These anti- À7 to 1 9 10 À4 M). Then, a control medium or 10 ng/mL PMA (positive control) was added for an additional 30 min. Cell supernatants harvested and tested for Pro-MMP-9 (a) and MPO (b) levels. Data are expressed as median (interquartile range), n = 14.
